<?xml version="1.0"?>
<rss version="2.0">
  <channel>
    <title>RxPG News : Antihypertensives</title>
      <link>http://www.rxpgnews.com/</link>
      <description>Medical News and Information</description>
      <pubDate>Thu, 25 Oct 2007 07:48:36 PST</pubDate>
      <language>en-us</language>
      <item>
        <title>CCB and ACE inhibitors reduce diabetes risk in Hispanic patients</title>
        <link>http://www.rxpgnews.com/antihypertensives/CCB_and_ACE_inhibitors_reduce_diabetes_risk_in_His_4415_4415.shtml</link>
        <category>Antihypertensives</category>
        <description>The combination of drugs traditionally used to control blood pressure might not be ideal for Hispanic patients, University of Florida researchers warn.</description>
        <pubDate>Thu, 08 Jun 2006 16:39:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/antihypertensives/CCB_and_ACE_inhibitors_reduce_diabetes_risk_in_His_4415_4415.shtml</guid>
      </item>
      <item>
        <title>ACE inhibitors implicated in birth defects</title>
        <link>http://www.rxpgnews.com/antihypertensives/ACE_inhibitors_implicated_in_birth_defects_4414_4414.shtml</link>
        <category>Antihypertensives</category>
        <description>The Food and Drug Administration is examining study data from Vanderbilt University Medical Center researchers, published this week in the New England Journal of Medicine, to determine if new warnings should be placed on common blood pressure medications indicating an increased risk of birth defects for babies whose mothers take these medications during the first trimester of pregnancy.</description>
        <pubDate>Thu, 08 Jun 2006 16:37:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/antihypertensives/ACE_inhibitors_implicated_in_birth_defects_4414_4414.shtml</guid>
      </item>
      <item>
        <title>Latest Data on Nebivolol, the Investigational Beta-Blocker Compound</title>
        <link>http://www.rxpgnews.com/antihypertensives/Latest_Data_on_Nebivolol_the_Investigational_Beta-_1516_1516.shtml</link>
        <category>Antihypertensives</category>
        <description>Mylan Laboratories Inc.,announced today that the results of new data on nebivolol,an investigational compound currently under review by the Food and Drug Administration for the treatment of hypertension,were presented at the 20th Annual Scientific Meeting of The American Society of Hypertension (ASH) held in San Francisco. </description>
        <pubDate>Thu, 19 May 2005 13:07:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/antihypertensives/Latest_Data_on_Nebivolol_the_Investigational_Beta-_1516_1516.shtml</guid>
      </item>
      <item>
        <title>Metoprolol Shows Promise in Pediatric Hypertension</title>
        <link>http://www.rxpgnews.com/antihypertensives/Metoprolol_Shows_Promise_in_Pediatric_Hypertension_1481_1481.shtml</link>
        <category>Antihypertensives</category>
        <description>AstraZeneca announced new data for beta-blocker TOPROL-XL® (metoprolol succinate) extended-release tablets in treating hypertension in pediatric patients. The data was presented today in a press briefing at the 20th annual scientific meeting of the American Society of Hypertension (ASH) in San Francisco.</description>
        <pubDate>Tue, 17 May 2005 08:35:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/antihypertensives/Metoprolol_Shows_Promise_in_Pediatric_Hypertension_1481_1481.shtml</guid>
      </item>
      <item>
        <title>Trends in the Prescribing of Thiazides for Hypertension</title>
        <link>http://www.rxpgnews.com/thiazides/Trends_in_the_Prescribing_of_Thiazides_for_Hyperte_1256_1256.shtml</link>
        <category>Thiazides</category>
        <description>Hypertension is common in affluent societies and a major risk factor for heart disease. In Canada, hypertension is the leading primary diagnosis for patient visits to physicians&#39; offices. Beyond recommending lifestyle changes such as losing weight, quitting smoking, and lowering salt and alcohol intake, prescription drugs are indicated in many patients. As a consequence, antihypertensive drugs are the leading category of prescription drugs in Canada, accounting for 20% of prescription drug sales.</description>
        <pubDate>Tue, 26 Apr 2005 22:26:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/thiazides/Trends_in_the_Prescribing_of_Thiazides_for_Hyperte_1256_1256.shtml</guid>
      </item>


  </channel>
</rss>
